EVMN Evommune, Inc.
$6.73▼ -1.17%
Healthcare
Other
After hours
$6.25▼ -7.08%
Oct 30, 6:02 PM ET
Volume 586.1K
Avg Volume (10D) 1.16M
Key Metrics & Fundamentals
Market Cap
$244.25M
P/E Ratio
–
Div Yield
0.00%
52W Range
4.94 - 33.20
% vs 50 MA
-23.43%
% vs 200 MA
-62.10%
RSI-14
49.5
MACD Histogram
+0.3500
Beta (1Y vs SPY)
1.03
Free Cash Flow
-$20.50M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$34.34M
COGS
–
Operating Exp
$34.90M
Operating Income
-$34.90M
EBIT
-$34.90M
Pretax Income
-$32.25M
Net Income
-$32.25M
EPS (Diluted)
-0.89
Price & Volume History
Loading chart…
Recent News
Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight
GlobeNewswire · Oct 19, 2026 1:00 PM ET
UBS Initiates Coverage on Evommune With Neutral Rating, $8 Price Target
MT Newswires · Oct 12, 2026 10:04 AM ET
EADV26: Key late-stage readouts from the conference
Clinical Trials Arena · Oct 5, 2026 7:57 AM ET
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
Business Wire · Oct 1, 2026 8:00 AM ET
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
Business Wire · Sep 23, 2026 4:05 PM ET
Evommune (EVMN) Drops EVO756 for Eczema. Can EVO301 Carry the Pipeline?
Insider Monkey · Sep 16, 2026 3:55 PM ET
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
BioPharma Dive · Sep 11, 2026 5:37 AM ET
Sector Update: Healthcare Stocks Decline in Afternoon Trading
MT Newswires · Sep 9, 2026 1:34 PM ET
This Biotech Has Lost 50%-Plus On Just One Drug; Why It's Still Trucking On
Investor's Business Daily · Sep 9, 2026 10:01 AM ET
Sector Update: Healthcare Stocks Mixed Premarket Wednesday
MT Newswires · Sep 9, 2026 9:16 AM ET
Financial Overview - Income Statement
Quarterly
Sep 2025
See EVMN's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.